期刊文献+

宫腔镜术后子宫内膜息肉复发的多因素分析 被引量:19

Multiplicity analysis on the recurrence of endometrial polyps after hysteroscopic surgery
下载PDF
导出
摘要 目的探讨宫腔镜联合药物治疗子宫内膜息肉患者的复发因素。方法收集我院2006年10月至2008年10月经宫腔镜和病理诊断为子宫内膜息肉的患者168例,分为四组,A组:52例,为初发息肉,术后未用药;B组:36例,术后炔诺酮治疗3个月;C组:26例,为复发息肉,术后未用药;D组:54例,术后炔诺酮治疗3~6个月。比较四组术后复发率并用Logistic回归法分析与复发可能的相关因素。结果总复发率为11.3%。四组复发率差异具有统计学意义,B组复发率最低,C组复发率最高(P<0.05)。息肉多发、腺肌瘤型息肉、乳腺癌tamoxifen治疗病史和既往内膜息肉病史与高复发率有关,术后药物治疗和术后妊娠与低复发率有关。结论子宫内膜息肉患者行宫腔镜监测下诊刮或息肉摘除术,术后加用炔诺酮治疗及术后妊娠对降低复发率有重要作用,是经济有效的治疗方法,值得推广。 Objective To investigate prognostic factors for endometrial polyps recurrence after complete hysteroscopy excision of polyps combined with medical treatment.Methods 168 patients with endometrial polyps after hysterscopic excision were collected and divided into four groups:group A(52 cases) was primary polyps,which was not given any treatment after operation;group B(36 cases) was primary polyps,which was given norethisterone for 3 months after operation;group C(26 cases) was recurrence polyps,which was not given any treatment after operation;group D(54 cases) was recurrence polyps,which was given norethisterone for 3-6 months after operation.Logistic regression analysis was used to assess the factors on recurrence.Results The overall rate of recurrence was 11.3%.There was a significant difference among four groups(P〈0.05),the recurrence of group B was the lowest and group C was the highest.Polyps number,polyps pathologic type,breast cancer patients with tamoxifen and previous polyps were independently associated with higher recurrence.Post-operative pregnancy and medical treatment were pr otective effcets.Conclusion Pregnancy and drugs have a protective effect on disease recurrence of endometrial polyps
出处 《海南医学》 CAS 2011年第10期75-77,共3页 Hainan Medical Journal
关键词 子宫内膜息肉 多因素分析 宫腔镜手术 Endometrial polyps Multiplicity Hysteroscopy surgery
  • 相关文献

参考文献12

  • 1陈忠年,沈铭昌,郭慕依.实用外科病理[M].上海:上海医科大学出版社,1997:228.
  • 2Clark TI, Khan KS, Gupta JK. Current practice for the treatment of benign intrauterine polys:a national questionaire survey of consultant gynaecologists in UK [J]. Eur J Obstet Gynecol Reprod Biol, 2002, 103(1): 65-67.
  • 3Taylor LJ, JacksonTL, Reid JG, et al. The differential expression of oestrogen receptors,progesterone receptors,bcl-2 and 1d-67 in endometrial polyps [J]. Br J Obstet Gynaecol, 2003, 110(9): 794-798.
  • 4Sant Ana de Almeida EC, Nogueira A.A, Candido dos Rcis F J, et al. expression of estrogen and progesterone receptors in endometrial polyps and adjacent endomctriurn in postmenopausal women [J]. Maturitas, 2004, 49(3): 229-233.
  • 5崔慧珠,贾琳钰.子宫内膜炎患者子宫内膜息肉的患病分析[J].中国医药,2006,1(6):373-374. 被引量:6
  • 6i Berzolla CE, Schnatz PF, O'Sullivan DM, et al. Dysplasia and malignancy in endocervical polyps [J]. J Womens Health (Larchmt). 2007, 16(9): 1317-1321.
  • 7Younis MT, lram S, Anwar B, et al. Women with asymptomatic cervical polyps may not need to see a gynaecologist or have them removed: an observational retrospective study of 1126 cases [J]. Eur J Obstet Gynecol Reprod Biol, 2010, 150(2): 190-194.
  • 8Bouda J Jr, Hradecky L, Rokyta Z. Hysteroscopic polypectomy versus fractionated curettage in the treatment of corporal polyps--recurrence of corporal polyps [J]. Ceska Gynekol, 2000, 65(3): 147-151.
  • 9陈正云,林俊,张信美.宫腔镜术后子宫内膜息肉复发危险因素分析[J].中国现代手术学杂志,2004,8(1):19-22. 被引量:24
  • 10Maia H Jr, Maltez A, Studart E, et al. Effect of previous hormone replacement therapy on endometrial polyps during menopause [J]. Gyneeol Endocrinol, 2004, 18(6): 229-304.

二级参考文献10

  • 1[1]Kommoss F, Karck U, Prmpeler H, et al. Steroid receptor expression in endometria from women treated with tamoxifen[J]. Gynecologic oncology, 1998,70(2):188-191.
  • 2[2]Kim MR, Kim YA, Jo MY, et al. High frequency of endometrial polyps in endometriosis[J]. J Am Assoc Gynecol Laparosc, 2003,10(1):46-48.
  • 3[3]Savelli L, De Iaco P, Santini D, et al. Hystopathologic features and risk factors for benignity, hyperplasia, and cancer in endometrial polyps[J]. J Am Assoc Gynecol Laparosc,2003,188(4):927-931.
  • 4[4]Bouda J Jr, Hradecky L, Rokyta Z. Hysteroscopic polypectomy versus fractionated curettage in the treatment of corporal polyps-recurrence of corporal polyps[J]. Ceska Gynekol,2000,65(3):147-151.
  • 5[5]Mittal K, Schwartz L, Goswami S, et al. Estrogen and progesterone receptor expression in endometrial polyps[J]. Int J Gynecol Pathol,1996,15(4):345-348.
  • 6[6]Maia H, Maltez A, Athayde C, et al. Proliferation profile of endometrial polyps in post-menopausal women[J]. Maturitas,2001,40(3):273-281.
  • 7[7]Tallini G , Vanni R, Ianfioletti G, et al. HMGI-C and HMGI(Y) immunoreactivity correlates with cytogenetic abnormalities in lipomas,pulmonary chondroid hamartomas,endometrial polyps,and uterine leiomyomas and is compatible with rearrangement of the HMGI-C and HMGI(Y) genes[J]. Lab Invest,2000,80(1):359-369.
  • 8[8]Goldenberg M, Nezhat C, Seidman DS. A randomized prospective study of the use of endometrial ablation for prevention of recurrent endometrial polyps in breast cancer patients receiving tamoxifen[J]. Prim Care Update Ob Gyns,1998,5(4):160.
  • 9[9]DeWaay DJ, Syrop CH,Nygaard IE,et al. Natural history of uterine polyps and leiomyomata[J]. Obstet Gynecol,2002,100(1):3-7.
  • 10[10]Gardner FJ, Konje JC, Abrams KR, et al. Endometrial protection from tamoxifen-stimulated changes by a levonorgestrel-releasing intrauterine system:a randomised controlled trial[J]. Lancet,2000,356(9243):1711-1717.

共引文献35

同被引文献143

引证文献19

二级引证文献217

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部